CeriBellCBLL -0.41%12 Debt-to-Equity is 0.16 as of Mar. 2026, which is 33% above its 10-year median of 0.12. GuruFocus rates CBLL with a GF Score™ of 12/100. The stock has 4 warning signs investors should review. Among 704 Medical Devices & Instruments companies, CeriBell ranks better than 58.38% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for CeriBell's Debt-to-Equity or its related term are showing as below:
CBLL'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.21 Med: 0.12 Max: 0.16
Current: 0.16
During the past 4 years, the highest Debt-to-Equity Ratio of CeriBell was 0.16. The lowest was -0.21. And the median was 0.12.
CBLL's Debt-to-Equity is ranked better than 58.38% of 704
companies
in the Medical Devices & Instruments industry
Industry Median: 0.225
vs CBLL: 0.16
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
CeriBell Debt-to-Equity Related Terms
CeriBell Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for CeriBell's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CBLL vs BBNX, SIBN, TCMD: Debt-to-Equity Comparison
For the Medical Devices subindustry, CeriBell's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CeriBell Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CeriBell's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where CeriBell's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CeriBell (CBLL) has a Debt-to-Equity of 0.16 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on CeriBell and its competitors. This is 33% above median its historical median of 0.12. According to the industry distribution chart, CeriBell ranks #293 out of 704 companies in the Medical Devices & Instruments industry, placing it in the top 41.6%.
Is CeriBell's Debt-to-Equity too high?
CeriBell's current Debt-to-Equity of 0.16 is 33% above median its 10-year median of 0.12. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. CeriBell's value of 0.16 is 28.9% below this industry median. Based on the distribution chart, CeriBell ranks #293 out of 704 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, CeriBell has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does CeriBell's Debt-to-Equity compare to BBNX and SIBN?
According to the Medical Devices & Instruments industry distribution chart, CeriBell ranks #293 out of 704 companies for Debt-to-Equity. This puts CeriBell in the upper half of its industry. The industry median Debt-to-Equity is 0.23. CeriBell's value of 0.16 is 28.9% below this benchmark. While the company's 10-year median is 0.12 vs. the industry median of 0.23, CeriBell has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CeriBell's current Debt-to-Equity of 0.16 is 28.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on CeriBell and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CeriBell's current Debt-to-Equity is 0.16, which is 33% above median its own 10-year median of 0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CeriBell stock overvalued right now?
CeriBell (CBLL) has a current Debt-to-Equity of 0.16. The current Debt-to-Equity is 0.16, which is 33% above median its 10-year median of 0.12 and 28.9% below the Medical Devices & Instruments industry median of 0.23. CeriBell's overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For CeriBell (CBLL), the current Debt-to-Equity is 0.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CeriBell Inc is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable, and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Its products are Point-of-Care EEG, Clarity, and EEG Portal.
12GF Score
Get the complete analysis for CBLL
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CBLL has been successfully added to your 
